- Went public, Sep 2005
- Raised $5M funding round, Aug 2024
- Raised $7.5M funding round, Jan 2023
About
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.
The company has an advanced pipeline of proprietary drug candidates in phase II and phase III clinical development that address inflammatory, liver, and metabolic diseases.
Can-Fite's platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer, and other pathological body cells, whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention.
The company's compounds bind with nM affinity to the A3AR and initiate deregulation of the NF-kB and Wnt signal transduction pathways, resulting in anti-inflammatory and anticancer effects.
Funding history · 18 rounds · $113.5M total
Q&A
- When did Can-Fite BioPharma last raise funding?
- Can-Fite BioPharma's most recent funding round was in April 2025, raising $3 million.
- What is the primary focus of Can-Fite BioPharma's drug development?
- Can-Fite BioPharma focuses on developing targeted drugs for cancer and inflammatory diseases, utilizing the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target.
- When did Can-Fite BioPharma go public on the TASE?
- Can-Fite BioPharma went public on the TASE in September 2005.
- What is the status of Namodenoson for pancreatic cancer treatment?
- In October 2024, the FDA granted Orphan Drug Designation to Can-Fite's Namodenoson for pancreatic cancer. In November 2024, Can-Fite achieved a milestone with the first patient dosing in the pancreatic cancer Phase IIa clinical trial.
- What is the latest development regarding Piclidenoson for veterinary osteoarthritis?
- In September 2024, Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, projecting an income of $325 million to Can-Fite over the next 10 years.
- What is the status of Can-Fite's CF602 for erectile dysfunction?
- In May 2024, Can-Fite received a Notice of Allowance from the European Patent Office for the treatment of erectile dysfunction with CF602.
- What is the status of Namodenoson for MASH patients?
- In May 2024, the FDA granted IND clearance for Namodenoson to treat MASH patients in a Phase IIb study. Can-Fite had submitted an IND application to the FDA in April 2024.
- What was a significant finding regarding Namodenoson's anti-cancer effects in the liver?
- In June 2024, breakthrough findings demonstrated Namodenoson's anti-cancer and protective effect mechanism in the liver.
- What is the employee count for Can-Fite BioPharma?
- Can-Fite BioPharma has 11-50 employees.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | canfite.com |
|---|---|
| facebook.com/CanFiteBioPharma |
Identifiers & details
| Founded | 1994-9 |
|---|---|
| Employees (exact) | 17 |
| Offices | Waltham |
| Market cap | $16.1M |
| Status reason | Public on TASE on Sep 2005;Public on NYSE on Jul 2025; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2025-07 | $15.0M | |||
| 2005-09 |